CompanyHURANasdaqTampa, FL

Kintara Therapeutics, Inc.

Kintara Therapeutics develops immuno-oncology therapeutics to overcome cancer immunotherapy resistance.

SEC EDGAR ClinicalTrials.gov

DEF 14ASep 28Latest SEC filing

Sep 24Latest story

September 2026

TuHURA draws two more tranches on Parkview credit line, each for $650,000

Sep 24FinancingKintara Therapeutics, Inc.

TuHURA Biosciences adopts inducement equity plan, adds detail in amended filing

Sep 17PeopleKintara Therapeutics, Inc.

TuHURA Biosciences draws $1.5 million more from Parkview credit line

Sep 4FinancingKintara Therapeutics, Inc.

August 2026

TuHURA draws two more tranches on $50 million Parkview credit line

Aug 21FinancingKintara Therapeutics, Inc.

TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programs

Aug 14Quarterly updateKintara Therapeutics, Inc.

July 2026

TuHURA Biosciences draws $1.5 million more under Parkview credit facility

Jul 29FinancingKintara Therapeutics, Inc.

TuHURA Biosciences draws $1.9 million more under Parkview credit line

Jul 7FinancingKintara Therapeutics, Inc.